| Roche Pharma (Schweiz) AG - Ocrevus subkutan 920 mg/23 ml, Injektionslösung |
| 68988 | | 01 | | Ocrevus subkutan 920 mg/23 ml | | Injektionslösung | | L04AA36 | | Ocrelizumab | | 15.11.2024 | | |
|
| Composition |
| ocrelizumabum 920 mg, hyaluronidasum humanum ADNr, trehalosum dihydricum, acidum aceticum glaciale, methioninum, polysorbatum 20, natrii acetas trihydricus, aqua ad iniectabile ad solutionem pro 23 ml corresp. natrium 8.4 mg. |
| Packungsbestandteile |
| Injection solution | | | | | | | | Active Agent | Dose |
|---|
| Ocrelizumabum | 920mg / 23ml |
| | BAG: Active Agent | Dose |
|---|
| Ocrelizumabum | 920 mg |
| | | | Inactive agents |
|---|
| Acidum Aceticum Glaciale | | Hyaluronidasum Humanum Adnr | | Methionine | | Sodium Acetate Trihydrate | | Polysorbatum 20 | | Trehalosum Dihydricum |
| |
|
| Package number | Package Size | EFP | CP | Category | SL | Out of trade (MedRef) |
|---|
| 001 | | 10648.94 | 11233.60 | A | SL | No |
|
